Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells
about
Targeting cellular metabolism to improve cancer therapeuticsThe sweet trap in tumors: aerobic glycolysis and potential targets for therapySafety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case studyOvarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolismThe reversal effects of 3-bromopyruvate on multidrug resistance in vitro and in vivo derived from human breast MCF-7/ADR cellsBreast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment.Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine.Hormone Resistance in Two MCF-7 Breast Cancer Cell Lines is Associated with Reduced mTOR Signaling, Decreased Glycolysis, and Increased Sensitivity to Cytotoxic Drugs.Kinetic analysis of intracellular Hoechst 33342--DNA interactions by flow cytometry: misinterpretation of side population status?Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway.Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells.Dichloroacetate restores drug sensitivity in paclitaxel-resistant cells by inducing citric acid accumulation.Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma.Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation.Targeting glucose metabolism in cancer: new class of agents for loco-regional and systemic therapy of liver cancer and beyond?Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance.Targeting the metabolic microenvironment of tumors.3-Bromopyruvate: targets and outcomes.Tumor glycolysis as a target for cancer therapy: progress and prospects.Concise review: Defining and targeting myeloma stem cell-like cells.Cancer stem cells, metabolism, and therapeutic significance.The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside.Targeting tumour energy metabolism potentiates the cytotoxicity of 5-aminolevulinic acid photodynamic therapy.Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate.Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells.Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.Regulation of Cancer Stem Cell Metabolism by Secreted Frizzled-Related Protein 4 (sFRP4).Inhibition of Glycolysis and Glutaminolysis: Emerging Drug Discovery Approach to Combat Cancer.p53 and metabolism: from mechanism to therapeutics.VDAC1 as Pharmacological Target in Cancer and Neurodegeneration: Focus on Its Role in Apoptosis.Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment.
P2860
Q24596727-216510A3-F542-46D9-962D-916274649672Q26766079-262E82E9-0C4E-4A13-B178-85235867D410Q26852150-AE1A6571-76C8-4D51-91A7-1712DD44CA75Q28538384-007EAA86-7E52-408F-8DA8-931917D0E787Q28544747-6C37B523-4D69-42DC-B3BC-EE9A99C3AE64Q34007740-BAD97CCA-19E2-4008-BD90-594C5964E940Q34104182-8778E8DF-13FB-448B-8CA7-5A945FA8674DQ34125846-9CD92A11-A7B2-4908-8F36-76C12309427BQ34470778-1873E50A-603E-4C8A-9ABB-8749945DC34FQ35008587-4963F06E-4A4A-4CDC-99EB-3D2730946778Q35176105-C4385A88-C9FC-4479-8B25-408A05FD4D74Q35232780-69265B21-E181-4265-940A-147A518A3506Q35788743-98574E49-BBF0-4189-B164-4C4DEFE04FAAQ36545216-162BB95E-45EF-4716-939E-F6378E822175Q36687966-C5912189-854F-4899-AEA3-D1323C1F5B31Q36815271-C99AF7A9-49B0-4F12-B169-53076AFC6B75Q37229190-AF7F3143-6F96-42CE-9D48-389CB3833C8CQ37980697-2D2F5742-EB44-45CD-891C-196B7BA9AA17Q38168262-BC0F4BC1-3DC7-4D3F-8B38-9427C03D3167Q38180656-27F5AE35-8E76-403F-BDAF-44E59288ABE9Q38728744-2D6F6A4F-33C1-466C-BD78-5BC4DFEF1A4FQ38837920-A24E035C-2F7A-4A69-9603-7C0101DCA609Q39125005-873F18B4-0412-4A38-A363-35EC6BE73229Q39402922-DA213024-EF9A-4289-A6F3-1FDF172EF224Q41174750-AC6256FD-3D33-49F1-B51E-F5364B8CB0B3Q47554666-83F069B2-0116-4D41-B9EF-8DA719CE5B2BQ48133992-E96B4AFF-08F1-4320-A1DF-94706EAB1DC5Q54978523-63171633-3FE1-4D61-8C0F-44F9D105BB40Q55002919-37E39A78-9D87-4E9F-A58A-9D7CBD9B092DQ55129102-C51BF785-C107-4061-A427-6332C2C58908Q55396364-F277049F-6194-4441-86F9-B47CF93410F2
P2860
Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Glycolysis inhibition inactiva ...... sensitivity in malignant cells
@ast
Glycolysis inhibition inactiva ...... sensitivity in malignant cells
@en
Glycolysis inhibition inactiva ...... sensitivity in malignant cells
@nl
type
label
Glycolysis inhibition inactiva ...... sensitivity in malignant cells
@ast
Glycolysis inhibition inactiva ...... sensitivity in malignant cells
@en
Glycolysis inhibition inactiva ...... sensitivity in malignant cells
@nl
prefLabel
Glycolysis inhibition inactiva ...... sensitivity in malignant cells
@ast
Glycolysis inhibition inactiva ...... sensitivity in malignant cells
@en
Glycolysis inhibition inactiva ...... sensitivity in malignant cells
@nl
P2093
P2860
P1433
P1476
Glycolysis inhibition inactiva ...... sensitivity in malignant cells
@en
P2093
Akira Sakai
Akishige Ikegame
Ayako Nakano
Daisuke Tsuji
Hiroe Amou
Hirokazu Miki
Kazuma Okano
Kohji Itoh
Kumiko Kagawa
P2860
P304
P356
10.1371/JOURNAL.PONE.0027222
P407
P577
2011-01-01T00:00:00Z